Trial Profile

Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pertuzumab (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab (Primary) ; Tucatinib (Primary)
Indications Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms TRAIN-4

Most Recent Events

17 Sep 2024 Trial design presented at the 49th European Society for Medical Oncology Congress
09 Jan 2024 Status changed from not yet recruiting to recruiting.
11 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com